Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at the Fondazione Prada in Milan
September 28, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
“Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)” poster exhibit“Effect of nasal anti-CD3 (foralumab) in healthy subjects” poster exhibit“Effect of nasal...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
September 23, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
September 21, 2022 07:30 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Continued Clinical Improvements in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) After Six Months of Dosing with Intranasal Foralumab
September 20, 2022 06:34 ET
|
Tiziana Life Sciences Ltd.
The second Expanded Access patient (EA2) demonstrated improved walking as measured by gait stability and enduranceThe patient showed clinically significant improvement in the Expanded Disability...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
September 16, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Grant received by the Brigham and Women’s Hospital to Explore the Use of Intranasal anti-CD3 mAb in Amyotrophic Lateral Sclerosis
September 15, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
September 09, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
August 25, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman
August 17, 2022 07:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 17, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of...
Tiziana Life Sciences Announces Presentation at Alzheimer’s Association International Conference® 2022 (AAIC®) Evaluating Intranasal anti-CD3 for the Potential Treatment of Alzheimer’s Disease
August 01, 2022 08:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...